{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-033668","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.527375+00:00","generated_at":"2026-05-17T08:44:38.314992+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Opus Genetics appoints Robert Gagnon as CFO effective September 2, 2025","bullets":["Annual base salary of $465,000, eligible for annual bonus up to 45% of base.","Stock option for 250,000 shares and restricted stock award for 200,000 shares, both vesting over four years.","Gagnon previously CFO of Remix Therapeutics and Verastem Oncology; has raised over $2B in capital.","Appointment is part of Opus's advancement of clinical pipeline for inherited retinal diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-033668","json":"https://secwatch.observer/filing/0001140361-25-033668.json","markdown":"https://secwatch.observer/filing/0001140361-25-033668.md","text":"https://secwatch.observer/filing/0001140361-25-033668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125033668/0001140361-25-033668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125033668/ef20054946_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:44:38.314992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}